OSE Immunotherapeutics Stock
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 2.242 EUR | -8.86% |
|
-14.75% | -56.47% |
| Market Cap | 52.73M 60.09M 49.8M 45.39M 84.96M 5.76B 85.57M 596M 231M 2.94B 226M 221M 9.46B | P/E 2026 * |
-1.72x | P/E 2027 * | -1.97x |
|---|---|---|---|---|---|
| Enterprise Value | 93.52M 107M 88.33M 80.49M 151M 10.21B 152M 1.06B 409M 5.22B 400M 392M 16.77B | EV / Sales 2026 * |
19.1x | EV / Sales 2027 * | 11x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
CBOE
| OSEp | Real-time | |
|
Tradegate
| 6OP | Real-time | |
|
Börse Stuttgart
| 6OP | Delayed | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time | |
|
Boerse Muenchen
| 6OP | Real-time |
Last Transcript: OSE Immunotherapeutics
| 1 day | -8.86% | ||
| 1 week | -14.75% | ||
| Current month | -30.29% | ||
| 1 month | -30.20% | ||
| 3 months | -26.49% | ||
| 6 months | -29.76% | ||
| Current year | -56.47% |
| 1 week | 2.24 |  | 2.79 |
| 1 month | 2.24 | | 3.32 |
| Current year | 2.24 | | 5.9 |
| 1 year | 2.24 | | 7.7 |
| 3 years | 2.24 | | 11.58 |
| 5 years | 2.24 | | 12.28 |
| 10 years | 2.24 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 2025-10-01 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 2025-08-19 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 2016-05-30 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 2017-06-13 |
| Director/Board Member | - | 2023-06-21 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/13/24 | Sell | Director | 30,000 | 0.1375% | ||
| 11/12/24 | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 6/21/24 | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.86% | -14.75% | -62.54% | -53.96% | 60.09M | |
| -0.14% | +4.33% | +9.88% | +31.73% | 47.97B | |
| -1.69% | +1.48% | +53.02% | +33.59% | 44.5B | |
| +2.56% | +7.34% | +382.17% | +594.81% | 43.93B | |
| +0.24% | +2.85% | +9.78% | +89.54% | 41.03B | |
| -0.62% | -1.11% | +4.70% | +46.02% | 29.85B | |
| -0.28% | +1.07% | +26.83% | +152.91% | 17.27B | |
| -0.46% | +1.20% | +26.78% | +41.32% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| +3.37% | +9.21% | +9.93% | - | 15.34B | |
| Average | -0.81% | +0.64% | +51.17% | +117.00% | 27.01B | |
| Weighted average by Cap. | +0.11% | +2.86% | +83.00% | +156.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.58M 4.63M 4.22M 7.89M 535M 7.95M 55.38M 21.45M 273M 20.97M 20.51M 879M | 10.53M 12M 9.95M 9.06M 16.97M 1.15B 17.09M 119M 46.09M 588M 45.06M 44.08M 1.89B |
| Net income | -30.59M -34.86M -28.89M -26.33M -49.28M -3.34B -49.63M -346M -134M -1.71B -131M -128M -5.49B | -21.47M -24.46M -20.27M -18.48M -34.59M -2.34B -34.83M -243M -93.97M -1.2B -91.85M -89.87M -3.85B |
| Net Debt | 40.79M 46.49M 38.53M 35.11M 65.72M 4.46B 66.19M 461M 179M 2.28B 175M 171M 7.32B | 63.08M 71.89M 59.58M 54.3M 102M 6.89B 102M 713M 276M 3.52B 270M 264M 11.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-25 | €2.242 | -8.86% | 320,479 |
| 26-09-24 | €2.460 | -5.31% | 104,668 |
| 26-09-23 | €2.598 | +0.62% | 360,766 |
| 26-09-22 | €2.582 | -0.31% | 47,367 |
| 26-09-21 | €2.590 | -1.52% | 87,018 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
